Oculogenex is a biopharmaceutical company founded and directed by an ophthalmologist retinal surgeon with patients in mind. It was founded out of passion and frustration shared with patients losing vision due to lack of therapeutic options. We have professional and scientific experience with retinal diseases, genetic variations in retinal and optic nerve diseases. We have built a team of experts in animal models of macular degeneration, antioxidant therapies for macular degeneration, medical and surgical treatments of retinal diseases and drug delivery methods. This specialized team has been built to utilize genetic engineering technology to improve vision for patients with degenerative eye diseases.
Employees: 1-10
Founded date: 2020
Investors 1
| Date | Name | Website |
| 22.01.2022 | MassChalle... | masschalle... |
Mentions in press and media 3
| Date | Title | Description |
| 17.12.2021 | MassChallenge Announces 2022 HealthTech Cohort | This 2022 cohort includes 24 startups, 15 of which will participate in the first PandemicX program. Boston, MA (December 17, 2021) - MassChallenge, the global network for innovators, today announces the 24 startups invited to participate... |
| 28.10.2021 | 36 MassChallenge Startup Winners Named from the 2021 U.S. Early Stage Cohort | 12th Annual MassChallenge Showcase & Awards highlights the diverse startup landscape Boston, MA – Now in its 12th year, MassChallenge, the global network for innovators, awarded 39 equity-free cash and investment prizes to 36 startup... |
| 03.03.2021 | Oculogenex wins first place in the International Winning Pitch Challenge - Retina 2021 | TORRANCE, Calif., March 3, 2021 /PRNewswire/ -- Oculogenex, a disruptive ocular gene therapy company, today announced that they won the first place prize at the international Winning Pitch Challenge – Retina 2021. The award was presented to... |